CERC Cerecor Inc.

5.26
-0.07  -1%
Previous Close 5.33
Open 5.45
Price To Book 10.73
Market Cap 224358246
Shares 42,653,659
Volume 151,737
Short Ratio
Av. Daily Volume 141,759

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data released December 5, 2016 - endpoint not met.
CERC-501
Smoking cessation
Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.
CERC-301
Major depressive disorder (MDD)
Phase 1 data due 1H 2019.
CERC-301
Neurogenic Orthostatic Hypotension (nOH)
Phase 1 data due 1H 2019.
CERC 801
Phosphoglucomutase 1 (PGM1) deficiency

Latest News

  1. CERC: Positive Results for Phase 1 Trial of CERC-301…
  2. Cerecor Announces Positive Interim Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (nOH)
  3. Cerecor Announces Leadership Changes
  4. CERC: Multiple Data Readouts in 2019; Commercial Unit Continues Growth…
  5. Cerecor Reports Fourth Quarter and Full Year 2018 Results
  6. Cerecor Increases Previously Announced Bought Deal of Common Stock to $10 Million
  7. Cerecor Announces $8 Million Bought Deal Offering
  8. Do Insiders Own Lots Of Shares In Cerecor Inc. (NASDAQ:CERC)?
  9. Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency
  10. Cerecor Announces CERC-301 Granted U.S. Patent
  11. Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland
  12. FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
  13. FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation
  14. Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
  15. CERC: Unveils Rare Pediatric Disease Programs…
  16. What Kind Of Share Price Volatility Should You Expect For Cerecor Inc (NASDAQ:CERC)?
  17. Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
  18. Cerecor Reports Third Quarter 2018 Results
  19. Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation
  20. Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism